Inclusion Criteria:

- Patients with laboratory-confirmed COVID-19 infection through a PCR test using a
nasopharyngeal swab specimen, or the presence of at least two of the following four
inflammatory criteria: C-reactive protein (CRP) level > 4 mg/dL, D-dimer level > 1
mg/L, ferritin level > 1000 ng/mL, along with fever ≥ 38 °C and respiratory distress
Patients having supplemental oxygen requirement. Patients who provide informed
consent to participate in the study. Patients having normal levels of serum Ca2+ and
K+; QT interval <450 ms at 12 derivations ECG (Colchicine has been associated with
potential cardiac side effects, including disturbances in electrolyte levels and QT
interval prolongation. Normal levels of these electrolytes help minimise the risk of
cardiac arrhythmias or other adverse events.

Exclusion Criteria:

Known hypersensitivity or allergy to colchicine or any of its excipients. Patients with
an estimated glomerular filtration rate (eGFR) below 45 mL/min/1.73 m^2 or advanced liver
disease (Child-Pugh Class B or C). Patients taking medications known to have significant
interactions with colchicine, such as strong CYP3A4 inhibitors (e.g., clarithromycin,
ketoconazole), P-glycoprotein inhibitors (e.g., cyclosporine), or medications associated
with myelosuppression (e.g., azathioprine, cyclophosphamide). Patients with pre-existing
medical conditions that, in the opinion of the investigator, could pose a significant
risk or interfere with the interpretation of the study results (e.g., severe heart
failure, uncontrolled arrhythmias, uncontrolled diabetes, or active malignancies).

Pregnant or lactating individuals. Patients deemed by the investigator to be in imminent
danger of death or unlikely to survive the duration of study due to some other disease